Androgen receptor coactivator p44/Mep50 in breast cancer growth and invasion

Journal of Cellular and Molecular Medicine

Volumn 14, Issue 12, 2010, Pages 2780-2789

  Peng, Yi ^a   Li, Yirong ^a   Gellert, Lan Lin ^a   Zou, Xuanyi ^a   Wang, Jun ^a   Singh, Baljit ^a   Xu, Ruliang ^a   Chiriboga, Luis ^a   Daniels, Garrett ^a   Pan, Ruimin ^a   Zhang, David Y ^b   Garabedian, Michael J ^a   Schneider, Robert J ^a   Wang, Zhengxin ^c   Lee, Peng ^a,d  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d DEPARTMENT OF VETERANS AFFAIRS   (United States)

Author keywords

Androgen receptor coactivator; Breast cancer; P44 mep50

Indexed keywords

ESTROGEN; ESTROGEN RECEPTOR; P44 PROTEIN, HUMAN; TRANSCRIPTION FACTOR;

ARTICLE; BREAST TUMOR; CANCER INVASION; CELL PROLIFERATION; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MAMMARY GLAND; METABOLISM; PAGET NIPPLE DISEASE; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CELL LINE, TUMOR; CELL PROLIFERATION; ESTROGENS; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MAMMARY GLANDS, HUMAN; NEOPLASM INVASIVENESS; RECEPTORS, ESTROGEN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS;

EID: 78650059955     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2009.00936.x     Document Type: Article

References (43)

1. Parkin DM, Bray F, Ferlay J, et al. Estimating the world cancer burden: globocan 2000. Int J Cancer. 2001; 94: 153-6.
2. Quiet CA, Ferguson DJ, Weichselbaum RR, et al. Natural history of node-positive breast cancer: the curability of small cancers with a limited number of positive nodes. J Clin Oncol. 1996; 14: 3105-11.
3. Boyer B, Valles AM, Edme N. Induction and regulation of epithelial-mesenchymal transitions. Biochem Pharmacol. 2000; 60: 1091-9.
4. Arias AM. Epithelial mesenchymal interactions in cancer and development. Cell. 2001; 105: 425-31.
5. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer. 2002; 2: 442-54.
6. Gotzmann J, Mikula M, Eger A, et al. Molecular aspects of epithelial cell plasticity: implications for local tumor invasion and metastasis. Mutat Res. 2004; 566: 9-20.
7. Hood JD, Cheresh DA. Role of integrins in cell invasion and migration. Nat Rev Cancer. 2002; 2: 91-100.
8. Cordera F, Jordan VC. Steroid receptors and their role in the biology and control of breast cancer growth. Semin Oncol. 2006; 33: 631-41.
9. Singh RR, Kumar R. Steroid hormone receptor signaling in tumorigenesis. J Cell Biochem. 2005; 96: 490-505.
10. Agoff SN, Swanson PE, Linden H, et al. Androgen receptor expression in estrogen receptor-negative breast cancer. Immunohistochemical, clinical, and prognostic associations. Am J Clin Pathol. 2003; 120: 725-31.
11. Lea OA, Kvinnsland S, Thorsen T. Improved measurement of androgen receptors in human breast cancer. Cancer Res. 1989; 49: 7162-7.
12. Soreide JA, Lea OA, Varhaug JE, et al. Androgen receptors in operable breast cancer: relation to other steroid hormone receptors, correlations to prognostic factors and predictive value for effect of adjuvant tamoxifen treatment. Eur J Surg Oncol. 1992; 18: 112-8.
13. Ando S, De Amicis F, Rago V, et al. Breast cancer: from estrogen to androgen receptor. Mol Cell Endocrinol. 2002; 193: 121-8.
14. Birrell SN, Bentel JM, Hickey TE, et al. Androgens induce divergent proliferative responses in human breast cancer cell lines. J Steroid Biochem Mol Biol. 1995; 52: 459-67.
15. Conzen SD. Minireview: nuclear receptors and breast cancer. Mol Endocrinol. 2008; 22: 2215-28.
16. Birrell SN, Hall RE, Tilley WD. Role of the androgen receptor in human breast cancer. J Mammary Gland Biol Neoplasia. 1998; 3: 95-103.
17. Hackenberg R, Hofmann J, Holzel F, et al. Stimulatory effects of androgen and antiandrogen on the in vitro proliferation of human mammary carcinoma cells. J Cancer Res Clin Oncol. 1988; 114: 593-601.
18. Poulin R, Baker D, Labrie F. Androgens inhibit basal and estrogen-induced cell proliferation in the ZR-75-1 human breast cancer cell line. Breast Cancer Res Treat. 1988; 12: 213-25.
19. Hackenberg R, Luttchens S, Hofmann J, et al. Androgen sensitivity of the new human breast cancer cell line MFM-223. Cancer Res. 1991; 51: 5722-7.
20. Honma N, Sakamoto G, Akiyama F, et al. Breast carcinoma in women over the age of 85: distinct histological pattern and androgen, oestrogen, and progesterone receptor status. Histopathology. 2003; 42: 120-7.
21. Heinlein CA, Chang C. Androgen receptor (AR) coregulators: an overview. Endocr Rev. 2002; 23: 175-200.
22. Gelmann EP. Molecular biology of the androgen receptor. J Clin Oncol. 2002; 20: 3001-15.
23. Chen Y, Sawyers CL, Scher HI. Targeting the androgen receptor pathway in prostate cancer. Curr Opin Pharmacol. 2008; 8: 440-8.
24. Wooster R, Mangion J, Eeles R, et al. A germline mutation in the androgen receptor gene in two brothers with breast cancer and Reifenstein syndrome. Nat Genet. 1992; 2: 132-4.
25. Lobaccaro JM, Lumbroso S, Belon C, et al. Male breast cancer and the androgen receptor gene. Nat Genet. 1993; 5: 109-10.
26. Zhu X, Daffada AA, Chan CM, et al. Identification of an exon 3 deletion splice variant androgen receptor mRNA in human breast cancer. Int J Cancer. 1997; 72: 574-80.
27. Lanzino M, De Amicis F, McPhaul MJ, et al. Endogenous coactivator ARA70 interacts with estrogen receptor alpha (ERalpha) and modulates the functional ERalpha/ androgen receptor interplay in MCF-7 cells. J Biol Chem. 2005; 280: 20421-30.
28. Hosohata K, Li P, Hosohata Y, et al. Purification and identification of a novel complex which is involved in androgen receptor-dependent transcription. Mol Cell Biol. 2003; 23: 7019-29.
29. Zhou L, Wu H, Lee P, et al. Roles of the androgen receptor cofactor p44 in the growth of prostate epithelial cells. J Mol Endocrinol. 2006; 37: 283-300.
30. Peng Y, Chen F, Melamed J, et al. Distinct nuclear and cytoplasmic functions of androgen receptor cofactor p44 and association with androgen-independent prostate cancer. Proc Natl Acad Sci USA. 2008; 105: 5236-41.
31. Liang JJ, Wang Z, Chiriboga L, et al. The expression and function of androgen receptor coactivator p44 and protein arginine methyltransferase 5 in the developing testis and testicular tumors. J Urol. 2007; 177: 1918-22.
32. Gao S, Lee P, Wang H, et al. The androgen receptor directly targets the cellular Fas/FasL-associated death domain protein-like inhibitory protein gene to promote the androgen-independent growth of prostate cancer cells. Molecular Endocrinol. 2005; 19: 1792-802.
33. Li Y, Wang L, Zhang M, et al. LEF1 in androgen-independent prostate cancer: regulation of androgen receptor expression, prostate cancer growth, and invasion. Cancer Res. 2009; 69: 3332-8.
34. Cai CQ, Peng Y, Buckley MT, et al. Epidermal growth factor receptor activation in prostate cancer by three novel missense mutations. Oncogene. 2008; 27: 3201-10.
35. Kollara A, Kahn HJ, Marks A, et al. Loss of androgen receptor associated protein 70 (ARA70) expression in a subset of HER2-positive breast cancers. Breast Cancer Res Treat. 2001; 67: 245-53.
36. Li P, Yu X, Ge K, et al. Heterogeneous expression and functions of androgen receptor co-factors in primary prostate cancer. Am J Pathol. 2002; 161: 1467-74.
37. Meister G, Eggert C, Buhler D, et al. Methylation of Sm proteins by a complex containing PRMT5 and the putative U snRNP assembly factor pICln. Curr Biol. 2001; 11: 1990-4.
38. Friesen WJ, Wyce A, Paushkin S, et al. A novel WD repeat protein component of the methylosome binds Sm proteins. J Biol Chem. 2002; 277: 8243-7.
39. Furuno K, Masatsugu T, Sonoda M, et al. Association of Polycomb group SUZ12 with WD-repeat protein MEP50 that binds to histone H2A selectively in vitro. Biochem Biophys Res Commun. 2006; 345: 1051-8.
40. Fabbrizio E, El Messaoudi S, Polanowska J, et al. Negative regulation of transcription by the type II arginine methyltransferase PRMT5. EMBO Rep. 2002; 3: 641-5.
41. Raaphorst FM, Meijer CJ, Fieret E, et al. Poorly differentiated breast carcinoma is associated with increased expression of the human polycomb group EZH2 gene. Neoplasia. 2003; 5: 481-8.
42. Bachmann IM, Halvorsen OJ, Collett K, et al. EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J Clin Oncol. 2006; 24: 268-73.
43. Collett K, Eide GE, Arnes J, et al. Expression of enhancer of zeste homologue 2 is significantly associated with increased tumor cell proliferation and is a marker of aggressive breast cancer. Clin Cancer Res. 2006; 12: 1168-74.